蕈狀肉芽腫（MF）：新型療法、未滿足的需求和目標產品展望報告，2026 年

市場概覽

• 法國蕈狀肉芽腫（MF）市場預計將從 2025 年的 1,400 萬美元成長到 2035 年的 2,600 萬美元。
• 以下因素正在推動市場成長：
• 標靶治療和生物製藥的應用日益增多
• 擴大皮膚T細胞淋巴瘤的臨床研究
• 未來的成長取決於安全性更高、能夠持續控制疾病的療法的出現。

蕈狀肉芽腫（MF）的新療法和TPP見解

Thelansis 發布的「蕈狀肉芽腫(MF)：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026 年」對該適應症的關鍵新興療法和主要藥物開發機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

蕈狀肉芽腫（MF）概述

蕈狀肉芽腫（MF）是最常見的皮膚T細胞淋巴瘤。皮膚T細胞淋巴瘤是一種罕見的癌症，起源於T細胞，但主要表現為皮膚病變。它通常進展緩慢，從斑塊狀病變發展為增厚的斑塊，只有少數患者會發展到更具侵襲性的階段。由於疾病在早期階段進展通常較慢，初始治療著重於皮膚標靶治療，例如局部用藥、照光治療和局部放射線治療，只有在疾病進展或症狀加重時才會增加治療強度。對於病情較重或出現治療抗藥性的患者，近年來全身性治療的選擇顯著增加。這包括針對癌變T細胞上特定標記的抗體療法，許多患者對抗體療法的耐受性優於傳統化療；此外，其他免疫療法和細胞療法也用於特定患者亞群。除了非常早期、局部疾病外，持續緩解或完全治癒仍然很困難，針對難治性病例的進一步標靶治療研究仍在繼續。

主要亮點

• 根據預測，德國蕈狀肉芽腫（MF）新病例數將從 2025 年的 525 例增加到 2035 年的 552 例。
• MF是皮膚T細胞淋巴瘤中最常見的一種，其特徵是病程呈慢性進行性。
• 晚期疾病診斷延遲和治療選擇有限仍然是主要的臨床挑戰。
• 目前仍有大量未被滿足的需求，即缺乏能夠提供持續療效並改善長期結果的治療方法。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興療法條件的患者
• 大公司
• 主要作用機制
• 發布日期預測等。
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要療法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興療法的見解
• 意識
• 預期用途/處理線
• 以滿足重大未滿足需求的程度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Virogen Biotechnology Inc.
• Soligenix
• SciTech Development, Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要療法概述及關鍵意見領袖見解
• 新興療法
• 重點
• 診斷和治療過程/演算法
• 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興療法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興療法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Mycosis Fungoides (MF) Emerging Therapy and TPP Insights

Thelansis's "Mycosis Fungoides (MF) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Mycosis Fungoides (MF) Overview

Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, a rare cancer that begins in T-cells but manifests primarily as skin lesions, typically progressing slowly from patches to thicker plaques over an extended period before, in a minority of patients, advancing to more aggressive stages. Because the disease is generally indolent early on, initial management centers on skin-directed therapies such as topical treatments, targeted light-based therapy, and localized radiation, with treatment intensity escalating only as disease stage advances or symptoms become more troublesome. For patients who progress to more advanced or treatment-resistant disease, systemic options have expanded meaningfully in recent years, including targeted antibody-based therapies that home in on specific markers found on the cancerous T-cells, offering better tolerability than traditional chemotherapy for many patients, alongside other immune and cell-directed treatments used for select patient subsets. Durable remission or cure remains difficult to achieve outside of very early, localized disease, and investigation continues into additional targeted therapies for treatment-resistant cases.

Key Highlights

• In Germany, incident Mycosis Fungoides (MF) cases are projected to increase from 525 in 2025 to 552 by 2035.
• MF is the most common form of cutaneous T-cell lymphoma, characterized by a chronic and progressive disease course.
• Delayed diagnosis and limited treatment options for advanced disease remain key clinical challenges.
• Significant unmet need persists for therapies that provide durable responses and improve long-term outcomes.

Market Overview

• The France MF market is projected to grow from $14M in 2025 to $26M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted and biologic therapies
• Growing clinical research in cutaneous T-cell lymphoma
• Future growth will depend on therapies offering durable disease control with improved safety profiles.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Virogen Biotechnology Inc.
• Soligenix
• SciTech Development, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)